Apollo Medical Holdings, Inc. reported a strong second quarter in 2022, with a 54% increase in total revenue to $269.7 million. However, net income attributable to ApolloMed decreased to $11.4 million, and EPS-diluted was $0.25. The company is reiterating its full-year guidance for total revenue, net income, EBITDA, and Adjusted EBITDA.
Total revenue increased by 54% to $269.7 million compared to the prior-year quarter.
Net income attributable to ApolloMed was $11.4 million, a decrease from $12.7 million in the prior-year quarter.
Earnings per share (diluted) decreased to $0.25 compared to $0.28 in the prior-year quarter.
Adjusted EBITDA increased by 14% to $36.9 million compared to the prior-year quarter.
ApolloMed is reiterating its guidance for the year ending December 31, 2022, with total revenue expected to be between $1,055.0 million and $1,085.0 million, net income between $38.0 million and $57.0 million, EBITDA between $81.0 million and $111.0 million, and Adjusted EBITDA between $136.0 million and $166.0 million.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance